FUNCTIONAL-PROPERTIES OF HETEROGENEOUS HUMAN ASIALO-C4 AND ITS ISOTYPES C4A AND C4B

被引:0
|
作者
SCHULTZ, DR
ARNOLD, PI
机构
[1] Department of Medicine, Division of Allergy and Immunology, University of Miami School of Medicine, Miami, Florida
关键词
(A) containing complement = (C) components {ieEAC1gp; EAC1gp; 4bhu} (C4b is the major cleavage fragment of human C4); {ieEAC1gp; 4bhu; 2ahu} (C2a is the major cleavage fragment of human C2); a suprabar indicates the component is activated; (NHS) a + symbol next to a component indicates it was treated with sialidase (e.g; C4b+); allotypes of C4A and C4B; C4A; C4B; C4A3; C4B1; DGVB[!sup]2+[!/sup; E; glucose gelatin Veronal buffer with calcium and magnesium; T[!sub]max[!/sub] of C2; time at which there is maximum formation of {ieEAC1gp; 2ahu} as determined by hemolysis after adding a C3 and C5–C9 mixture; isotypes of C4; normal human serum; SA; sensitized with rabbit IgG antibody; Sheep erythrocytes; sialic acid;
D O I
10.1016/S0171-2985(11)80320-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The fourth component of human complement (C4) is encoded at two separate but closely linked loci within the MHC on the short arm of chromosome 6. Thus, there are two types of C4 protein in most individual and pooled normal human sera (NHS): C4A and C4B. Incubation of individual sera, pooled NHS, or purified heterogeneous C4 (C4A/C4B) with bacterial sialidase at 37-degrees-C increased C-mediated hemolysis of antibody-sensitized sheep erythrocytes 1.54- to 1.93-fold. Comparative studies of T(max) of human C2, using asialo-C4 or buffer-treated C4 on EAC1gpBAR and extrapolation to time 0 indicated a z value 4-fold higher with asialo-C4. This indicated that more hemolytically active C42BAR complexes are available with sialidase-treated C4 compared to untreated C4. There was no appreciable difference in the % I-125-C4 bound to EAC1gpBAR (sialidase- or buffer-treated). Sera from two different blood donors with C4A3 phenotype (C4BQ0), two different donors with C4B1 phenotype (C4AQ0), and serum from an individual heterozygous deficient at both C4A3 and C4B1 regions (A3, AQ0; B1, BQ0) were investigated. The C4 allotypes, purified from these sera, were treated with sialidase; the C4A3 was enhanced in hemolytic assays by sialidase-treatment (1.52- to 2.3-fold), whereas the C4B1 allotype was not enhanced. Fluorometric determinations revealed that approximately the same percentage of sialic acid was released from sialidase-treated C4A3 and C4B1. Therefore, the increase in hemolytic titer observed after treatment of NHS or purified heterogeneous C4 with sialidase is a property of C4A3 but not a property of C4B1.
引用
收藏
页码:90 / 102
页数:13
相关论文
共 50 条
  • [41] Hysteresis of human complement C4A to C4B binding in hemolytic activities and inhibition by immune complex aggregates
    Zhou, Danlei
    Liu, Xiaoping
    Coss, Samantha
    Yu, Chack-Yung
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [42] Complete complement components C4A and C4B deficiencies in human kidney diseases and systemic lupus erythematosus
    Yang, Y
    Lhotta, K
    Chung, EK
    Eder, P
    Neumair, F
    Yu, CY
    JOURNAL OF IMMUNOLOGY, 2004, 173 (04): : 2803 - 2814
  • [43] Novel techniques for definitive analyses of human complement C4A and C4B gene dosage variations in SLE
    Chung, EK
    Yung, Y
    Higgins, GC
    Rennebohm, RM
    Yu, CY
    PEDIATRIC RESEARCH, 2002, 51 (04) : 13A - 13A
  • [44] THE RELATIVE ROLES OF C4A AND C4B IN PREVENTION OF IMMUNE PRECIPITATION, SOLUBILIZATION AND IMMUNE ADHERENCE
    HOLME, ER
    VEITCH, J
    JOHNSTON, A
    MCKAY, IC
    WHALEY, K
    RHEUMATOLOGY INTERNATIONAL, 1992, 12 (05) : 187 - 190
  • [45] Allelic distribution of complement components BF, C4A, C4B, and C3 in Psoriasis vulgaris
    Cislo, M
    Halasa, J
    Wasik, F
    Nockowski, P
    Prussak, M
    Manczak, M
    Kusnierczyk, P
    IMMUNOLOGY LETTERS, 2002, 80 (03) : 145 - 149
  • [46] Substitution of the C4A 1101proline with the C4B 1101leucine decreases the apparent avidity of C4A for CR1.
    Reilly, BD
    MOLECULAR IMMUNOLOGY, 1998, 35 (6-7) : 396 - 396
  • [48] Improved method for the allelic definition of C4A and C4B polymorphism (HLA class III)
    Zorzetto, M
    Campo, I
    Cortelazzo, AG
    Panelli, S
    Cuccia, M
    BIOTECHNIQUES, 2001, 30 (05) : 976 - +
  • [49] Copy Number Analysis of Complement C4A, C4B and C4A Silencing Mutation by Real-Time Quantitative Polymerase Chain Reaction
    Paakkanen, Riitta
    Vauhkonen, Hanna
    Eronen, Katja T.
    Jarvinen, Asko
    Seppanen, Mikko
    Lokki, Marja-Liisa
    PLOS ONE, 2012, 7 (06):
  • [50] CLEAVAGE OF C4B BY C3B INACTIVATOR - PRODUCTION OF A NICKED FORM OF C4B, C4B', AS AN INTERMEDIATE CLEAVAGE PRODUCT OF C4B BY C3B INACTIVATOR
    NAGASAWA, S
    ICHIHARA, C
    STROUD, RM
    JOURNAL OF IMMUNOLOGY, 1980, 125 (02): : 578 - 582